Daniel Morgensztern, MD, on Updates on EGFR-Mutant NSCLC, Amivantamab, and Osimertinib

Posted: Thursday, February 1, 2024

Daniel Morgensztern, MD, of Washington University School of Medicine, discusses phase III findings of two key studies—MARIPOSA and MARIPOSA2—which explored the question of whether combining amivantamab with lazertinib could address resistance and improve clinical outcomes without chemotherapy for patients with EGFR-mutant NSCLC. He also describes results from the FLAURA2 trial, which suggested osimertinib in combination with platinum plus pemetrexed may improve progression-free survival vs osimertinib monotherapy in this population.

---